In this video, a patient describes her remarkable initial response to medical weight management, losing 8 kg across her first two weeks to move from 116 kg to 108 kg. More impactful than the numerical loss was the immediate resolution of chronic emotional eating and boredom snacking, shifting her relationship with nourishment toward eating strictly for sustenance rather than emotion. Body composition assessments verified a pronounced drop in visceral fat while safely protecting lean skeletal muscle. Experiencing no nausea or abdominal cramps, her journey highlights how rapid initial progress can occur comfortably under dedicated medical direction.
Key points
Lost 8 kg in just two weeks, reducing from 116 kg to 108 kg.
Substantial reduction in emotional snacking and boredom-driven eating.
Marked decrease in visceral fat while preserving functional muscle.
No significant nausea or gastric discomfort reported during the therapy.
This video follows a patient who lost 8 kg in two weeks, moving from 116 kg to 108 kg, with follow-up showing a clear reduction in visceral fat and preserved muscle. The most meaningful change for her was stopping emotional and boredom eating, so she began eating for hunger rather than throughout the day.
The story shows that a non-surgical sleeve approach is not only about appetite. Body composition, symptoms and sustainability matter too. The patient reported no troublesome cramps or nausea during the period shown. That is her personal experience, and a rapid early rate should not become a target for every case.
For questions about visceral fat, start with the guide to visceral-fat score, waist and InBody. For realistic expectations, read the Mounjaro results timeline, then review how to protect muscle during weight loss. The patient’s improvement in boredom eating is part of the interpretation, so appetite and behaviour follow-up sit alongside visceral-fat and muscle measures. Rapid loss in this patient’s experience does not remove the need to ask about symptoms, fluids, nutrition and sustainability.
Frequently asked questions
Visceral fat is fat around organs in the abdomen, and its assessment needs context from body composition and health. In the video, follow-up showed a reduction, but an InBody value alone is not a diagnosis. See the visceral-fat, waist and InBody guide.
Start by separating physical hunger from triggers such as boredom or stress, and note situations and meals without self-blame. In the video, the patient reported improvement with her weight plan, but emotional eating may also need behavioural and nutrition support alongside medical care.
That rate belongs to one monitored patient’s experience and is not a universal target or promise of safety. The clinician reviews composition, symptoms and the reason for change, because rapid shifts can involve fluid as well as fat and other factors.
In this case, appetite and boredom eating fell noticeably, but response differs. A non-surgical option may suit some patients and is not a universal prescription. The clinician reviews suitability, nutrition and follow-up. For context, read what to expect from Mounjaro results.
An InBody visceral-fat value and waist circumference may not move together. Learn what each estimate represents, how to standardise measurement and how to read the trend without treating either number as a diagnosis.
When might tirzepatide affect appetite and weight, and how should progress at 4, 12 and 20 weeks be read? A realistic guide to trial averages and individual results.
Weight loss is not a race to the lowest number. Learn how adequate food, suitable protein, resistance exercise and strength follow-up can help preserve muscle.